TBRG Should I Buy
-
$
0.000
0.000(0.000%)
At close0.000(0.000%)Aft-market
ET
TruBridge Inc (TBRG) is not a good buy at the moment for a beginner investor with a long-term strategy. The stock is currently facing significant negative catalysts, including financial reporting issues, declining net income, and bearish technical indicators. While the company has a stable Electronic Health Records business and potential growth opportunities in Revenue Cycle Management, the risks outweigh the potential rewards given the current circumstances.
The stock is in a bearish trend with MACD negatively expanding, RSI indicating oversold conditions at 17.628, and bearish moving averages (SMA_200 > SMA_20 > SMA_5). The current pre-market price of $15.4 is near the support level of S1: 15.395, but the overall technical outlook remains weak.
Potential growth opportunities in the Revenue Cycle Management business and stable Electronic Health Records business.
Rosen Law Firm investigation into potentially misleading business information, delayed financial reporting, errors in 2024 and 2025 financial statements, and deficiencies in internal controls over financial reporting. These issues have caused significant stock price declines recently.
In Q3 2025, revenue increased by 1.66% YoY to $86.1M, but net income dropped by -161.79% YoY to $5.42M, and EPS fell by -160.66% YoY to $0.37. Gross margin improved slightly by 2.36% YoY to 43.35%. Overall, financial performance is weak, with declining profitability.
RBC Capital resumed coverage with a Sector Perform rating and a $23 price target. While the company has growth opportunities, RBC remains cautious due to execution risks and recent periods of low growth.
